JW Group relocates to Gwacheon, bolstering R&D

JW Group said it has moved its headquarters to the JW Gwacheon Building, located in Gwacheon, Gyeonggi Province, to enhance research and development (R&D). 

The JW Gwacheon Building is based on a large-scale convergence research facility and holds all of the group's R&D personnel.

The new building in Gwacheon will house core affiliates such as JW Pharmaceutical, C&C Research Labs, JW Creagene, JW Life Sciences, and JW Bioscience. 

The company reportedly invested about 120 billion won ($90.6 million) in the building, including land acquisition and construction costs.

The new building has a gross floor area of 35,557 square meters and is a 15-story-high building.

The group's research facilities will occupy five floors and will house the group's researchers, including the new drug, formulation, and raw material research centers, which were previously scattered throughout the greater Seoul area.

"In addition to innovative new drugs, which are the group's main research field, the building will focus on developing future growth engines such as next-generation intravenous shots, precision in vitro diagnostic products, and advanced medical devices," the group said. "Notably, we expect to create synergies and improve research efficiency by integrating and operating our data science platforms, such as JWELRY and CLOVER, as well as research equipment and reagents. "

The group also plans to expand the use of electronic journals and electronic research notes to the entire research sector, upgrade the R&D platform that combines AI and machine learning technologies, and build a smart lab environment by introducing automated raw material synthesis robots.

"JW Gwacheon Building will be operated as a space to realize the value of respect for life," said a JW Group representative. "As the R&D center is responsible for the future of JW, we will conduct innovative studies at the facility."